KRAS is a target of miR-27a in tumors, particularly in ESCC, and downregulation of the KRAS oncogene may provide a novel treatment strategy for cancer patients by attenuating tumor growth. This evidence concerns the gene KRAS and esophageal squamous cell carcinoma.